natgillin/translations-raw huggingface dataset:
4.4 Special warnings and precautions for use 
4.4 Posebna opozorila in previdnostni ukrepi Gastrointestinalna perforacija
Caution with regards to the use of naldemedine should be exercised in patients with any conditions which might result in impaired integrity of the gastrointestinal tract wall (e.g. peptic ulcer disease, Ogilvie's syndrome, malignancy of the GI tract, Crohn's disease). 
Pri bolnikih s katero koli boleznijo, ki bi lahko okrnila integriteto stene gastrointestinalnega trakta (npr. ulkusna bolezen, Ogilviejev sindrom, maligni tumorji prebavil, Crohnova bolezen), je potrebna previdnost pri uporabi naldemedina.
Proportion of SBM Responders 
Povprečna pogostnost BM v izhodišču
Adverse reactions presented by System Organ Class and frequency in patients with chronic non-cancer pain and opioid-induced constipation 
Neželeni učinki, navedeni po organskih sistemih in pogostnosti, pri bolnikih s kronično nerakasto bolečino in zaprtjem, povzročenim z opioidi
The pharmacokinetics of naldemedine between subjects with mild or moderate hepatic impairment and healthy subjects with normal hepatic function were similar. 
Farmakokinetika naldemedina pri preiskovancih z blago ali zmerno okvaro jeter in pri zdravih preiskovancih z normalnim delovanjem jeter je bila podobna.
• If you experience a serious allergic reaction, stop taking Rizmoic and see a doctor or go to a hospital straight away.. Serious allergic reactions include: swelling of the hands, feet, ankles, face, lips or throat which may cause difficulty swallowing or breathing, itching of the skin and nettle rash. 
Resne alergijske reakcije vključujejo: otekanje dlani, stopal, gležnjev, obraza, ustnic ali žrela, ki lahko oteži požiranje ali dihanje, srbenje kože in koprivnica.
These were mild or moderate in severity and resolved. 
Ti so bili blago do zmerno izraženi in so izzveneli.
Tablet core: Mannitol, croscarmellose sodium (see section 2 under ‘Rizmoic contains sodium') and magnesium stearate. 
Sredica tablete: manitol, premreženi natrijev karmelozat (glejte poglavje 2 pod 'Zdravilo
- if you have cancer of the brain or central nervous system, multiple sclerosis, or Alzheimer's disease. 
• bolezen, ki povzroča hudo vnetje prebavnega trakta, na primer Crohnovo bolezen; - če imate raka možganov ali centralnega živčevja, multiplo sklerozo ali Alzheimerjevo bolezen.
Round, approximately 6.5 mm diameter, yellow tablet debossed with '222' and Shionogi logo on one side and '0.2' on the other side. 
Okrogla rumena tableta s premerom približno 6,5 mm z vtisnjenim napisom '222' in logotipom družbe
Each film-coated tablet contains 200 micrograms naldemedine (as tosylate). 
Ena filmsko obložena tableta vsebuje 200 mikrogramov naldemedina (v obliki tosilata).
Opioid withdrawal syndrome aOne serious report of hypersensitivity reaction was observed in clinical studies with naldemedine. 
Splošne težave in spremembe na mestu aplikacije sindrom odtegnitve opioidov aIz kliničnih študij z naldemedinom izvira eno resno poročilo o preobčutljivostni reakciji.
Patients with cardiovascular disease risk factors were not excluded from the naldemedine clinical trial programme, with BMI ≥ 30 kg/m2, and a medical history of hypertension and/or dyslipidaemia being the most commonly reported risk factors. 
Dejavniki tveganja, o katerih so najpogosteje poročali, so bili indeks telesne mase (ITM) ≥ 30 kg/m2 in anamneza hipertenzije in/ali dislipidemije.
Immune system disorders 
Bolezni imunskega sistema preobčutljivosta
A total of 547 patients in Study V9231, 551 patients in Study V9232 and 1246 patients in Study V9235 were randomised in a 1:1 ratio to receive 200 micrograms of naldemedine or placebo once daily for 12 weeks for Studies V9231 and V9232, for 52 weeks for Study V9235. 
V9235 so randomizirali v razmerju 1:1 na prejemanje 200 mikrogramov naldemedina ali placeba enkrat na dan, za 12 tednov v študijah V9231 in V9232 ter za 52 tednov v študiji V9235.
No dose adjustment is required in patients with renal impairment (see section 5.2). 
Okvara ledvic Pri bolnikih z okvaro ledvic prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
Contents of the pack and other information 
Shranjevanje zdravila Rizmoic Vsebina pakiranja in dodatne informacije
Opioid withdrawal syndrome aMedDRA Preferred Terms: abdominal pain, abdominal pain upper, abdominal pain lower and abdominal discomfort 
Splošne težave in spremembe na mestu aplikacije sindrom odtegnitve opioidov aPreferenčni izrazi MedDRA: bolečina v trebuhu, bolečina v zgornjem delu trebuha, bolečina v spodnjem delu trebuha in nelagodje v trebuhu.
Naldemedine (N=621) 
Naldemedin (N=621)
Rizmoic has no influence on your ability to drive or to use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Rizmoic ne vpliva na sposobnost upravljanja vozil in strojev.
Naldemedine did not cause significant induction of CYP1A2, CYP2B6 or CYP3A4 isozymes. 
Naldemedin ni povzročil pomembne indukcije izocimov CYP1A2,
NAME OF THE MEDICINAL PRODUCT 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
The mean baseline SBMs was 1.31, 1.17, and 1.60, for Studies V9231, V9232 and V9235 respectively. 
Povprečni izhodiščni SBM v študijah V9231, V9232 oziroma V9235 so bili 1,31, 1,17 oziroma 1,60.
You should stop taking Rizmoic when you stop taking your opioid pain medicine. 
Ko prenehate jemati opioidno zdravilo, prenehajte jemati tudi zdravilo Rizmoic.
Dose-dependent increases in gastrointestinal-related adverse reactions, including abdominal pain, diarrhoea, and nausea, were observed. 
Opazili so od odmerka odvisno zvečanje s prebavili povezanih neželenih učinkov, ki so obsegali bolečino v trebuhu, drisko in navzeo.
- Each tablet contains 200 micrograms of naldemedine (as tosylate). 
- Ena tableta vsebuje 200 mikrogramov naldemedina (v obliki tosilata).
Naldemedine (N=276) 
Naldemedin (N=276)
8448CN, 
Heerenveen, 8448CN, Nizozemska
How to store Rizmoic 
Shranjevanje zdravila Rizmoic
CI=Confidence Interval *Statistically significant: p-values based on the Cochran-Mantel-Haenszel test. ** p<0.0001 *** p=0.0003 for study V9231 and p=0.0011 for study V9232 
*** p=0,0003 v študiji V9231 in p=0,0011 v študiji V9232
• watery eyes or runny nose 
• solzenje ali izcedek iz nosu,
Each tablet contains 200 micrograms naldemedine (as tosylate). 
Ena tableta vsebuje 200 mikrogramov naldemedina (v obliki tosilata).
The frequency categories are defined using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon 
Neželeni učinki 200-mikrogramskih tablet naldemedina pri bolnikih s kronično nerakasto bolečino in OIC in pri bolnikih z rakom in OIC, o katerih so poročali v kliničnih študijah, so navedeni v preglednicah v skladu z razvrstitvijo po organskih sistemih MedDRA. Skupine pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000) in neznana pogostnost
• inability to sleep 
• nespečnost.
Tel.: +48 (12) 653 15 71 e-mail: biuro@molteni.com.pl 
Tel.: +48 (12) 653 15 71
• pupils dilating 
• razširjene zenice,
The discontinuation rate due to gastrointestinal treatment emergent adverse events with naldemedine 200 micrograms compared to placebo was 3.2% and 1% respectively in patients with chronic non-cancer pain and OIC and 4.5% and 0% respectively for patients with cancer and OIC. 
oziroma 1 % pri bolnikih s kronično nerakasto bolečino in OIC in 4,5 % oziroma 0 % pri bolnikih z rakom in OIC.
Placental transfer of [carbonyl-14C]-naldemedine-derived radioactivity was observed in pregnant rats. 
Pri brejih podganah so ugotovili prehajanje radioaktivnosti, ki je izvirala iz [karbonil-14C]naldemedina, skozi posteljico.
Naldemedine has not been studied in patients with severe hepatic impairment. 
Pri bolnikih s hudo okvaro jeter naldemedina niso proučevali.
In the pre- and postnatal development study in rats, one dam died at parturition at 1000 mg/kg/day, and poor nursing, suppression of body weight gain and decrease in food consumption were noted at 30 and 1000 mg/kg/day. 
Opazili so tudi slabo dojenje, zmanjšan prirast telesne mase in zmanjšano uživanje hrane pri odmerkih 30 in 1.000 mg/kg/dan.
The peritoneum is the lining of your gut area. 
Peritonej prekriva predel črevesa v trebušni votlini;
Naldemedine is primarily metabolised by CYP3A with some contribution from UGT1A3 and is a substrate of P-glycoprotein (P-gp) (see section 5.2). 
Naldemedin se pretežno presnavlja s CYP3A, nekaj prispeva tudi UGT1A3, in je substrat
One serious case of abdominal pain and one serious case of nausea were reported in patients with chronic non-cancer pain and OIC. 
Pri bolnikih s kronično nerakasto bolečino in OIC so poročali o enem resnem primeru bolečine v trebuhu in enem resnem primeru navzee.
• stomach pain 
• bolečina v trebuhu,
• diarrhoea 
• driska.
Severe hepatic impairment 
Huda okvara jeter
Abdominal adverse reactions (e.g. abdominal pain, vomiting and diarrhoea) have been reported with Rizmoic. 
Pri zdravilu Rizmoic so poročali o abdominalnih neželenih učinkih (npr. bolečini v trebuhu, bruhanju in driski).
Very Common Common 
Organski sistem Zelo pogosti
Change in frequency of CSBMs per week (LS Mean) 
Sprememba pogostnosti BM na teden
Abdominal pain, diarrhoea, nausea and vomiting were the most commonly reported adverse reactions in clinical studies with patients with chronic non-cancer pain and OIC and with patients with cancer and OIC. 
Neželeni učinki, o katerih so najpogosteje poročali v kliničnih študijah pri bolnikih s kronično nerakasto bolečino in OIC in pri bolnikih z rakom in OIC, so bili bolečina v trebuhu, driska, navzea in bruhanje.
Talk to your doctor or pharmacist if you are taking any of the following medicines: - Rifampicin, clarithromycin or telithromycin (antibiotic medicines) - Itraconazole or ketoconazole (medicines to treat fungal infections) - Ritonavir, indinavir or saquinavir (medicines for HIV infection) - Phenytoin, carbamazepine, phenobarbital (medicines to treat epilepsy) - St John's wort (Hypericum perforatum), a herbal medicine used for depression 
- ritonavir, indinavir ali sakvinavir (zdravila za okužbo s HIV), - fenitoin, karbamazepin, fenobarbital (zdravila za zdravljenje epilepsije),
Diarrhoea Abdominal painb Nausea 
Bolezni prebavil driska bolečina v trebuhua gastrointestinalna perforacija
Rizmoic contains the active substance naldemedine. 
Rizmoic vsebuje natrij') in magnezijev stearat.
If you are being treated with an opioid medicine for chronic non-cancer pain. 
Pri jemanju tega zdravila se lahko pojavijo naslednji neželeni učinki: Če se zdravite z opioidnim zdravilom zaradi kronične nerakaste bolečine.
Film coating 
Okvara jeter
Rizmoic 200 micrograms film-coated tablets naldemedine 
IME ZDRAVILA Rizmoic 200 mikrogramov filmsko obložene tablete naldemedin
(1 to 1.3-fold) for peak plasma concentration and area under the plasma concentration-time curve was observed after once daily multiple dose administration in the fasted state for 10 days. 
Po dajanju večkratnih odmerkov enkrat na dan na tešče 10 dni so ugotovili rahlo (1 do 1,3-kratno) kopičenje, kar zadeva najvišjo plazemsko koncentracijo in površino pod krivuljo plazemska koncentracija-čas.
Tablet core 
PRETISNI OMOT
Check with your doctor or pharmacist if you are not sure. 
Posvetujte se z zdravnikom ali farmacevtom, če jemljete katero od naslednjih zdravil:
System Organ Class 
Organski sistem Pogosti
In Study V9235, the three most common types of pain were back pain (58.0%); osteoarthritis (9.5%) and neck pain (8.1%). 
(58,0 %); osteoartritis (9,5 %) in bolečina v vratu (8,1 %).
There is no risk of interaction with concomitant use of mild CYP3A inhibitors. 
Pri sočasni uporabi blagih inhibitorjev CYP3A ni tveganja, da bi prišlo do medsebojnega delovanja.
Naldemedine (N=273) 
Naldemedin (N=273)
Concomitant use of strong CYP3A inducers such as St. John's wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital and phenytoin is not recommended. 
Sočasna uporaba močnih induktorjev CYP3A, na primer šentjanževke (Hypericum perforatum),
Taking into account the PRAC Assessment Report on the PSUR(s) for naldemedine, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za naldemedin je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke: Imetnik dovoljenja za promet z zdravilom je v svoji globalni podatkovni bazi ugotovil devet primerov gastrointestinalne perforacije.
Concomitant use with strong CYP3A inhibitors and inducers Concomitant use of naldemedine with strong CYP3A inhibitors (e.g. grapefruit juice, itraconazole, ketoconazole, ritonavir, indinavir, saquinavir, telithromycin and clarithromycin) leads to an increase in naldemedine exposure and may increase the risk of adverse reactions. 
ketokonazol, ritonavir, indinavir, sakvinavir, telitromicin in klaritromicin) zveča izpostavljenost naldemedinu in lahko zveča tveganje za pojav neželenih učinkov.
Croscarmellose sodium Magnesium stearate 
Jedro tablete manitol premreženi natrijev karmelozat magnezijev stearat Filmska obloga tablete hipromeloza smukec rumeni železov oksid (E172)
• vomiting 
• bruhanje.
Cases of gastrointestinal perforation have been reported in the post-marketing setting, including fatal cases, when naldemedine was used in patients who were at an increased risk of gastrointestinal (GI) perforation, (e.g. diverticular disease and underlying malignancies of the gastrointestinal tract or peritoneal metastases). 
perforacije (npr. divertikuloza in osnovne maligne bolezni gastrointestinalnega trakta ali peritonealne metastaze).
Do not worry. 
Naj vas ne skrbi.
* if needed 
* če je potrebno
Date of first authorisation: 18 December 2008 
Datum prve odobritve: 18. december 2008
In this case, you will have to take the tablets only once or twice a day. 
V tem primeru boste tablete jemali samo enkrat ali dvakrat na dan.
Take care if you are taking the following medicines: 
Bodite previdni, če jemljete naslednja zdravila:
Date of latest renewal: 26 August 2013 
Datum zadnjega podaljšanja: 26. avgust 2013
In open continuation trials lasting for more than three years there were no signs of decreasing efficacy. 
V odprtih nadaljevalnih preskušanjih, ki so trajala več kot 3 leta, ni bilo znakov zmanjševanja učinkovitosti.
Simply leave out that dose completely and then take your next dose at the right time. 
Enostavno izpustite ves odmerek in vzemite naslednjega ob pravem času.
The relevance for humans is unknown. 
Pomen za ljudi ni znan.
Also, it can pass into the breast milk and can reach your baby. 
Poleg tega lahko prehaja v materino mleko in tako pride do otroka.
Swallow the tablets with water. 
Tablete pogoltnite z vodo.
747 70 Opava-Komarov Czech Republic 
747 70 Opava-Komarov Ceška Republika
Do not try to make up for the missed dose. 
Ne poskušajte nadomestiti pozabljenega odmerka.
The absolute bioavailability is greater than 90 % and the maximum plasma concentrations occur between 1 and 3 hours. 
Absolutna biološka uporabnost je večja od 90 % in največjo koncentracijo v plazmi doseže med 1 in 3 urami.
Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol. 
Bodite previdni, če jemljete kakršnakoli zdravila, ki vas pomirijo (imajo sedativni učinek), ali pijete alkohol.
This finding is not clinically relevant to man. 
Ta izsledek ni klinično pomemben za ljudi.
Mania and delirium 
Manija in delirij
You can then build up the dose again, as you did the first time. 
Nato odmerek povečujete na enak način, kot ste ga prvič.
This reduces the risk of worsening symptoms. 
Tako preprečite nevarnost, da bi se simptomi poslabšali.
If the problems persist more than a few weeks, your doctor may need to adjust your treatment. 
Če težave trajajo dlje kot nekaj tednov, bo moral zdravnik morda zdravljenje prilagoditi.
The frequency category is probably not greater than “uncommon”. 
Njihova kategorija pogostnosti verjetno ni višja od kategorije “občasni”.
GALIEN LPS 98 rue Bellocier 89100 Sens France 
GALIEN LPS 98 rue Bellocier 89100 Sens Francija
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. 
Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsbuje za vas pomembne podatke!
This includes medicines, herbal remedies, health foods or supplements that you have obtained without a prescription. 
To velja tudi za zdravila, zdravilne rastlinske pripravke, biohrano ali prehranska dopolnila, ki ste jih kupili brez recepta.
The latter finding was not observed in pigmented rats, nor in a 2-year albino mouse carcinogenicity study or in any other species investigated. 
Tovrstnega učinka niso opazili pri pigmentiranih podganah niti v 2-letni študiji o karcinogenosti pri albino miših ali katerikoli drugi proučevani živalski vrsti.
Pramipexole was not genotoxic. 
Pramipeksol ni genotoksičen.
The potential effects of pramipexole on reproductive function have been investigated in rats and rabbits. 
Morebitni učinek pramipeksola na reproduktivno funkcijo so proučevali pri podganah in zajcih.
• if you are allergic to pramipexole or to any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na pramipeksol ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
H-2100 Gödöllő, 
2100 Gödöllő Madžarska
Out of these, approximately 1,000 were in more advanced stages, received concomitant levodopa therapy, and suffered from motor complications. 
Od teh jih je približno 1.000 v bolj napredovalih stadijih sočasno prejemalo levodopo in so trpeli za motoričnimi zapleti.
It can be used alone or in combination with levodopa (another medicine for Parkinson's disease). 
Lahko ga uporabljamo samostojno ali v kombinaciji z levodopo (drugo zdravilo za Parkinsonovo bolezen);
If you have moderate or severe kidney disease, your doctor will prescribe a lower dose. 
Če imate zmerno hudo ali hudo ledvično bolezen, vam bo zdravnik predpisal manjši odmerek.
Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities. 
Poslabšanje zajema zgodnejše pojavljanje simptomov zvečer (ali celo popoldne), povečanje simptomov in njihovo širjenje na druge okončine.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
There is no clinical experience with massive overdose. 
Ni kliničnih izkušenj z izrazito prevelikimi odmerki.
However, these studies did not indicate direct or indirect harmful effects with respect to male fertility. 
Niso pa študije prikazale neposrednega ali posrednega škodljivega učinka na plodnost pri samcih.
If you stop taking your tablets for more than a few days and want to restart the treatment, you must start again at the lowest dose. 
Če tablet niste jemali dlje od nekaj dni in jih želite ponovno jemati, morate ponovno začeti z najmanjšim odmerkom.
If you have to stop taking this medicine, your doctor will reduce the dose gradually. 
Če ga morate prenehati jemati, vam bo zdravnik postopno zmanjševal odmerek.
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). 
Neželeni učinki so navedeni po organskih sistemih in razvrščeni po pogostnosti (pričakovano število bolnikov, ki bodo doživeli neželen učinek) v naslednje skupine: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Pharmacotherapeutic group: anti-Parkinson drugs, dopamine agonists, ATC code: N04BC05 
Farmakoterapevtska skupina: antiparkinsoniki, agonisti dopamina, oznaka ATC: N04BC05.
Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements. 
Spodbujanje teh receptorjev sproži živčne impulze v možganih, ki nadzorujejo telesne gibe.
Approximately 90 % of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces. 
Približno 90 % odmerka, označenega s 14C, se izloči preko ledvic, medtem ko v blatu zasledimo manj kot 2 %.
However, the marketing authorisation holder shall submit periodic safety update reports for this medicinal product if the product is included in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. 
Vendar pa mora imetnik dovoljenja za promet za to zdravilo predložiti redno posodobljena poročila o varnosti zdravila, če je zdravilo vključeno v seznam referenčnih datumov Unije (seznam EURD), opredeljen v členu 107c(7) Direktive
The tablet can be divided into equal halves. 
Tableto lahko razdelimo na enaki polovici.
Initial treatment 
Začetno zdravljenje
Such effect was not observed in patient studies. 
Teh učinkov v preskušanjih pri bolnikih niso opazili.
Neuroleptic malignant syndrome 
Nevroleptični maligni sindrom
• treat the symptoms of primary Parkinson's disease in adults. 
• zdravljenje simptomov primarne Parkinsonove bolezni pri odraslih.
Patients should be regularly monitored for the development of impulse control disorders. 
Bolnike je treba redno spremljati zaradi možnega razvoja motenj nadzora impulzov.
• cisplatin (to treat various types of cancers) 
• cisplatin (zdravilo za zdravljenje različnih oblik raka)
Clinical efficacy and safety in Parkinson's disease 
Klinična učinkovitost in varnost pri Parkinsonovi bolezni
TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG United Kingdom 
Brampton Road, Hampden Park Eastbourne, East Sussex BN22 9AG Velika Britanija
Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following: 
Obvestite svojega zdravnika, če ste imeli ali se je pri vas razvil katerakoli simptomov, zlasti izmed naslednjih:
• quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria)) 
• kinin (zdravilo, ki ga lahko uporabljajo za preprečevanje bolečih nočnih krčev v nogah in zdravljenje oblike malarije, imenovane malarija falciparum (maligna malarija))
The elimination half-life (t½) varies from 8 hours in the young to 12 hours in the elderly. 
Razpolovna doba odstranjevanja se giblje od 8 ur pri mlajših bolnikih do 12 ur pri starejših.
In humans, the protein binding of pramipexole is very low (< 20 %) and the volume of distribution is large (400 l). 
Pri človeku je vezava pramipeksola na beljakovine v plazmi zelo majhna (< 20 %) volumen porazdelitve pa je velik (400 l).
• Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include: 
• nezmožnost upreti se impulzu, težnji ali skušnjavi po dejanjih, ki bi lahko škodila vam ali drugim, kot so:
• Abnormal dreams 
• nenormalne sanje,
There is no pharmacokinetic interaction with selegiline and levodopa. 
Ni farmakokinetičnega medsebojnega delovanja s selegilinom in levodopo.
Hallucinations or somnolence can occur. 
Lahko se pojavijo zaspanost in halucinacije.
It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of postural hypotension associated with dopaminergic therapy. 
Priporočljivo je, da spremljamo krvni tlak zlasti na začetku odmerjanja zaradi splošnega tveganja posturalne hipotenzije ob dopaminskem zdravljenju.
Read the package leaflet before use 
Pred uporabo preberite priloženo navodilo!